Overview
- Embecta reported weak second-quarter results that it disclosed on May 5, 2026, cutting fiscal‑year revenue guidance and causing the stock to fall about 57% in a single session.
- Plaintiff complaints filed after that disclosure allege Embecta and certain officers made false or misleading statements and concealed weakness in the U.S. pen‑needle segment that made guidance unattainable.
- On July 23, 2026 several plaintiff law firms issued notices reminding investors of the August 17, 2026 deadline to move for appointment as lead plaintiff in the consolidated federal case.
- Under the PSLRA the court will consider competing lead‑plaintiff motions after August 17, typically choosing the mover with the largest financial stake to select lead counsel and set litigation strategy.
- No class has been certified yet, absent class members retain rights without filing, and the case will next proceed through contested leadership fights, possible consolidation, discovery, class‑certification briefing, and either settlement or trial.